These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle. Serre SB; Jensen SB; Ghanem L; Humes DG; Ramirez S; Li YP; Krarup H; Bukh J; Gottwein JM Antimicrob Agents Chemother; 2016 Jun; 60(6):3563-78. PubMed ID: 27021330 [TBL] [Abstract][Full Text] [Related]
5. Ng TI; Tripathi R; Reisch T; Lu L; Middleton T; Hopkins TA; Pithawalla R; Irvin M; Dekhtyar T; Krishnan P; Schnell G; Beyer J; McDaniel KF; Ma J; Wang G; Jiang LJ; Or YS; Kempf D; Pilot-Matias T; Collins C Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084747 [TBL] [Abstract][Full Text] [Related]
6. In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants. Verbinnen T; Fevery B; Vijgen L; Jacobs T; De Meyer S; Lenz O Antimicrob Agents Chemother; 2015 Dec; 59(12):7548-57. PubMed ID: 26392483 [TBL] [Abstract][Full Text] [Related]
7. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a. Palanisamy N; Danielsson A; Kokkula C; Yin H; Bondeson K; Wesslén L; Duberg AS; Lennerstrand J Antiviral Res; 2013 Jul; 99(1):12-7. PubMed ID: 23648709 [TBL] [Abstract][Full Text] [Related]
8. Han B; Parhy B; Lu J; Hsieh D; Camus G; Martin R; Svarovskaia ES; Mo H; Dvory-Sobol H J Clin Microbiol; 2019 Apr; 57(4):. PubMed ID: 30728196 [TBL] [Abstract][Full Text] [Related]
9. Unexpected Replication Boost by Simeprevir for Simeprevir-Resistant Variants in Genotype 1a Hepatitis C Virus. Murai K; Shimakami T; Welsch C; Shirasaki T; Liu F; Kitabayashi J; Tanaka S; Funaki M; Omura H; Nishikawa T; Sumiyadorj A; Honda M; Kaneko S Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661883 [TBL] [Abstract][Full Text] [Related]
10. [Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1]. Şanlıdağ T; Sayan M; Akçalı S; Kasap E; Buran T; Arıkan A Mikrobiyol Bul; 2017 Apr; 51(2):145-155. PubMed ID: 28566078 [TBL] [Abstract][Full Text] [Related]
11. Prevalence of baseline NS3 resistance-associated substitutions (RASs) on treatment with protease inhibitors in patients infected with HCV genotype 1. Costa VD; Delvaux N; Brandão-Mello CE; Nunes EP; de Sousa PSF; de Souza Rodrigues LLLX; Lampe E; do Amaral Mello FC Clin Res Hepatol Gastroenterol; 2019 Nov; 43(6):700-706. PubMed ID: 30880098 [TBL] [Abstract][Full Text] [Related]
12. Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir. Berger KL; Triki I; Cartier M; Marquis M; Massariol MJ; Böcher WO; Datsenko Y; Steinmann G; Scherer J; Stern JO; Kukolj G Antimicrob Agents Chemother; 2014; 58(2):698-705. PubMed ID: 24217701 [TBL] [Abstract][Full Text] [Related]
13. Pre-existing resistance associated polymorphisms to NS3 protease inhibitors in treatment naïve HCV positive Pakistani patients. Khan HU; Khan S; Shah MA; Attaullah S; Malik MA PLoS One; 2020; 15(4):e0231480. PubMed ID: 32275694 [TBL] [Abstract][Full Text] [Related]
14. Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a. Guo Z; Black S; Hu Y; McMonagle P; Ingravallo P; Chase R; Curry S; Asante-Appiah E J Biol Chem; 2017 Apr; 292(15):6202-6212. PubMed ID: 28228479 [TBL] [Abstract][Full Text] [Related]
16. Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 Gammeltoft KA; Zhou Y; Duarte Hernandez CR; Galli A; Offersgaard A; Costa R; Pham LV; Fahnøe U; Feng S; Scheel TKH; Ramirez S; Bukh J; Gottwein JM Antimicrob Agents Chemother; 2021 Aug; 65(9):e0268020. PubMed ID: 34097489 [TBL] [Abstract][Full Text] [Related]
17. The Investigation of Drug Resistance Substitutions in NS3 Protease Sequence of Hepatitis C Virus from Non-Responder Patients. Nejabat N; Hosseini SY; Sarvari J; Gorzin AA; Fattahi MR; Rasoolian M Asian Pac J Cancer Prev; 2019 Aug; 20(8):2311-2317. PubMed ID: 31450900 [TBL] [Abstract][Full Text] [Related]
18. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors. Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279 [TBL] [Abstract][Full Text] [Related]
19. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies. Lenz O; Verbinnen T; Fevery B; Tambuyzer L; Vijgen L; Peeters M; Buelens A; Ceulemans H; Beumont M; Picchio G; De Meyer S J Hepatol; 2015 May; 62(5):1008-14. PubMed ID: 25445400 [TBL] [Abstract][Full Text] [Related]
20. Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses. Gottwein JM; Jensen SB; Li YP; Ghanem L; Scheel TK; Serre SB; Mikkelsen L; Bukh J Antimicrob Agents Chemother; 2013 Mar; 57(3):1291-303. PubMed ID: 23274664 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]